DiscoverX Premium Plus listing

Faraday Wharf, Innovation Birmingham Campus
Holt St, Birmingham Science Park Aston
B7 4BB
United Kingdom

Tel: +44 (0)121 260 6142

Email: [email protected]


DiscoveRx is a leading provider of next generation proprietary platforms for both target-based and phenotypic drug discovery. The company holds extensive intellectual property for its core technology platforms, which have been utilized to develop and commercialize industry leading panels of over 1,000 target-based and primary cell based assay solutions for Oncology, Metabolic Disease, Inflammation, CNS and Cardiovascular drug discovery research. Many of DiscoveRx’s innovative solutions have been widely adopted in pharmaceutical, biotechnology and academic laboratories worldwide.

Upcoming events

  • Biologics & Biosimilars Congress in Berlin on Feb 1st, 2016
    Feb 1-2, 2016 at the Maritim proArte Hotel, Berlin, Germany.

    Visit us at booth 23 at the Biologics & Biosimilar Congress, to learn about exciting new cell-based assays for immune-oncology (iOnc) & biosimilar development 

    iOnc Assays

    - New assays for PD-1, CD40 and more

    - Cytotoxicity assays for co-cultures

    - Simple assays, rapid results

    Biosimilar Assays

    - Validated assay for Bevacizumab

    - Frozen ready-to-use assays for 20+ biosimilars

    - High accuracy, precision and reproducibility

    Session talks at the conference on behalf of DiscoveRx

    - Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development -Abhishek Saharia, Ph.D, Director, Cell-based Assays, DiscoveRx, USA 

    15:20 – 15:50, Monday 1st February, Day 1, Track 1, Antibody Based Therapeutics

    - Paul Caldwell Ph.D,QC Scientist, Cell Based Assays, Covance Laboratories Ltd

    09:45 – 10:15, Tuesday 2nd February, Day 2, Track 3, Overcoming Regulation & CMC Hurdles for Biosimilar Development

    Poster presentations at the conference on behalf of DiscoveRx

    - Improved Cell-Based Assays To Assess Therapeutic Molecules Against Immune Checkpoint Receptors such as PD-1, PD-L1 and PD-L2

    - Ready-to-use potency assays for anti-VEGF drugs like Bevacizumab

    Come visit us at booth 23 to learn how you can win a mini iPad!

  • 3rd Immunotherapy of Cancer Conference (ITOC3)

Listed in categories

HTS | Outsourcing |

Related posts: